In this article, we will discuss Durvalumab (Geriatric Use-3). So, let’s get started.
Of the 265 patients with ES-SCLC treated with Durvalumab in combination with chemotherapy, 101 (38%) patients were 65 years or older and 19 (7.2%) patients were 75 years or older. There were no clinically meaningful differences in safety or efficacy between patients 65 years or older and younger patients.